Publications by authors named "Andrea Veatch"
Article Synopsis
- IMbrella A is a Phase III study that allowed patients from earlier atezolizumab trials, like IMpower133, to continue receiving treatment for extensive-stage small cell lung cancer (SCLC) with atezolizumab plus chemotherapy after the initial trials closed.
- In IMbrella A, 18 out of 26 eligible patients rolled over for further treatment, and results showed that median follow-up was 59.4 months with estimated three-, four-, and five-year overall survival rates of 16%, 13%, and 12%, respectively.
- The study reported that 16.7% of patients experienced serious adverse events, with only one grade two hypothyroidism noted,
J Immunother Cancer
October 2021
Article Synopsis
- Immune checkpoint inhibition therapy has shown promise for improving outcomes in advanced non-small cell lung cancer, but there's a need for better predictive biomarkers; a blood test called host immune classifier (HIC) was evaluated for this purpose in a real-world study.*
-
- The INSIGHT study enrolled over 3,570 NSCLC patients and assessed their survival based on HIC designation (HIC-H or HIC-C) and treatment type, revealing that HIC-H patients had significantly longer overall survival compared to HIC-C patients across various treatment regimens, including ICI therapies.*
-
- The findings indicate that HIC testing can independently predict patient survival outcomes regardless of the programmed death ligand 1 (PD-L1)
